Real-world Time to Discontinuation of First-Line Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma.
Current Medical Research and Opinion（2023）
关键词
Venetoclax,obinituzumab,chronic lymphocytic leukemia,tumor lysis syndrome,time to discontinuation,retrospective study
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要